Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENELUX CorpGNLX · Entity 1116 | Vice President, Finance | September 11, 2023 | September 12, 2023 |
| Kairos Pharma, LTD.KAPA · Entity 8244 | Chief Financial Officer | October 08, 2025 | November 26, 2025 |
| Newton Golf Company, Inc.SPGC · Entity 8169 | Chief Financial Officer | September 09, 2024 | September 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENELUX Corp
Report date September 11, 2023 · Filed September 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.40 · Expires 2033-09-10 | Direct | 40,000 |
Reported balance
After 2023-09-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-09-11 · Grant · Acquired 40,000 · Balance 40,000 F1: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.
Kairos Pharma, LTD.
Report date October 08, 2025 · Filed November 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 293,039 |
Reported balance
After 2025-10-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-10-08 · Grant · Acquired 152,672 · Balance 293,039 F1: Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date. F2: Consists of (1) 140,367 shares of common stock and (2) 152,672 RSUs which remain subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date.
F2: Consists of (1) 140,367 shares of common stock and (2) 152,672 RSUs which remain subject to vesting.
Newton Golf Company, Inc.
Report date September 09, 2024 · Filed September 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2031-09-09 | Direct | 36,000 |
Reported balance
After 2024-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-09 · Grant · Acquired 36,000 · Balance 36,000 F1: Effective September 9, 2024, the reporting person was granted options to purchase an aggregate of 36,000 shares vesting as follows: 1/3 of the options will vest 12 months after the vesting commencement date and 1/36th of the total shares will vest at the end of each month thereafter until the options are fully vested or the reporting person's continuous service terminates, whichever occurs first. The exercise price of the options is $3.00 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective September 9, 2024, the reporting person was granted options to purchase an aggregate of 36,000 shares vesting as follows: 1/3 of the options will vest 12 months after the vesting commencement date and 1/36th of the total shares will vest at the end of each month thereafter until the options are fully vested or the reporting person's continuous service terminates, whichever occurs first. The exercise price of the options is $3.00 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2025 Filed Nov 26, 2025 17:24 UTC | Kairos Pharma, LTD. KAPA · Entity 8244 | GrantCOMMON STOCK | 152,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-025198 · ownership.xml · nonDerivative · entry 1 Samuelson Doug · CIK 0001943326 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,039 F1 · shares: Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date. F2 · balance_after: Consists of (1) 140,367 shares of common stock and (2) 152,672 RSUs which remain subject to vesting. Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 06:03 UTC | Kairos Pharma, LTD. KAPA · Entity 8244 | PurchaseCOMMON STOCK | 2,500 | $1.50 | $3,750.00 |
DisclosureSEC source: 0001493152-24-047526 · ownership.xml · nonDerivative · entry 1 Samuelson Doug · CIK 0001943326 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,796 Read SEC document |
| September 09, 2024 Filed Sep 12, 2024 21:56 UTC | Newton Golf Company, Inc. SPGC · Entity 8169 | GrantOptions to Purchase Common Stock · Derivative | 36,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-24-036096 · ownership.xml · derivative · entry 1 Samuelson Doug · CIK 0001943326 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common · 36,000 shares Expires 2031-09-09 F1 · price: Effective September 9, 2024, the reporting person was granted options to purchase an aggregate of 36,000 shares vesting as follows: 1/3 of the options will vest 12 months after the vesting commencement date and 1/36th of the total shares will vest at the end of each month thereafter until the options are fully vested or the reporting person's continuous service terminates, whichever occurs first. The exercise price of the options is $3.00 per share. F1 · derivative.exercise_date: Effective September 9, 2024, the reporting person was granted options to purchase an aggregate of 36,000 shares vesting as follows: 1/3 of the options will vest 12 months after the vesting commencement date and 1/36th of the total shares will vest at the end of each month thereafter until the options are fully vested or the reporting person's continuous service terminates, whichever occurs first. The exercise price of the options is $3.00 per share. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 20:25 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $22.40 | $0.00 |
DisclosureSEC source: 0001209191-23-049103 · doc4.xml · derivative · entry 1 Samuelson Doug · CIK 0001943326 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-09-10 F1 · derivative.exercise_date: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 20:17 UTC | GENELUX Corp GNLX · Entity 1116 | SaleCommon Stock | 1,297 | $23.73 | $30,777.81 |
DisclosureSEC source: 0001209191-23-046885 · doc4.xml · nonDerivative · entry 1 Samuelson Doug · CIK 0001943326 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,303 F1 · shares: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $23.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 17, 2023 Filed May 2, 2023 20:23 UTC | GENELUX Corp GNLX · Entity 1116 | GrantCommon Stock | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026491 · doc4.xml · nonDerivative · entry 1 Samuelson Doug · CIK 0001943326 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,600 F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.